– Recent entry into the cosmeceuticals sector with launch of proprietary line of products
– Completion of bio-efficacy study evaluating avenanthramides in exercise-induced inflammation with results expected by year-end
– Results from animal studies evaluating bioavailability of impregnated CoQ10 with beta glucan expected Q1 2018
EDMONTON, ALBERTA–(Marketwired – Nov. 15, 2017) – Ceapro Inc. (TSX VENTURE:CZO) (“Ceapro” or the “Company”) a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today its financial results for the three-month and nine-month periods ended September 30, 2017 and provided an overview of recent operational highlights.
Financial Highlights for the Third Quarter 2017
- Total sales of $3,600,000 for the quarter ended September 30, 2017 compared to $3,018,000 in Q3 2016;
- Gross margin of $1,873,000 for the quarter ended September 30, 2017 compared to $1,893,000 in Q3 2016;
- Income from operations of $830,000 for the quarter ended September 30, 2017 compared to $1,051,000 in Q3 2016; and
- Net profit after tax of $296,000 for the quarter ended September 30, 2017 compared to $645,000 in Q3 2016.
“As previously announced, we have increased our investments in our technologies as well as accelerated R&D investments in our product pipeline as a step toward our long-term goal of transforming Ceapro from a manufacturing company to a full-fledged biopharmaceutical company,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro. “On a short-term basis, to further de-risk and expand our base business in cosmeceuticals, we have made a deliberate first step to achieve this through the acquisition of JuventeDC. In addition to potentially bring more financial security, we expect this strategic move to be a catalyst to ultimately ensure our planned transition into large potential markets. Specifically, this will enable Ceapro to reach the end customer for the first time with high-end cosmeceutical formulations utilizing our two value drivers, beta glucan and avenanthramides, and in addition, given the potential to develop dry products using our PGX technology, position us to offer new chemical complexes of beta glucan impregnated with various bio actives to be included into topical cosmeceutical formulations to treat various skin conditions. The hypothesis being that beta glucan will act as a delivery system.”
“On the financial results, the significant sales increase observed in Q3 2017 over Q3 2016 as well as over Q1 and Q2 2017 is mainly due to increased sales of avenanthramides. We are very pleased with the continued growth of avenanthramides, especially in the hair care sector. Regarding sales of beta glucan, while major orders received at the end of 2015 and delivered during the first two quarters of 2016 have not been repeated yet given the dilution factor involved in final products like facial masks, we are very encouraged by an expected replenishment of beta glucan stocks in Q1 2018, especially for the Asian market,” Mr. Gagnon added.
Beta Glucan Program Highlights
Ceapro's research program for the development of beta glucan as an active ingredient in functional food/drink and nutraceuticals is progressing very well.
The Company's bioavailability study being conducted in collaboration with researchers at The University of Alberta (“U of A”) is well underway. These animal studies are designed to assess the potential for improved bioavailability of Ceapro's new proprietary water soluble chemical complex (iBg-CoQ10) compared to commercially available CoQ10. Ceapro expects results from these studies during Q1 2018.
Decisions are being made for the final formulation of beta glucan for the upcoming clinical study to assess its potential as a cholesterol reducer. The Company plans to file its Clinical Trial Application with Health Canada by year end.
Avenanthramides Program Highlights
The Company's ongoing clinical study assessing avenanthramides as an anti-inflammation product has been completed with The University of Minnesota. Results are currently being analyzed and should be submitted for publication by year end. Results from this study could support the launch of avenanthramides as an active ingredient for functional food to be sold by major players in the food industry.
PGX Enabling Technology Update
Following the completion of its pilot scale facility for its proprietary PGX enabling technology, Ceapro's expert team has delivered required quantities of dry beta glucan for assessment of final formulations to be used in the upcoming clinical study to assess beta glucan as a cholesterol reducer when administered orally.
Collaboration with McMaster University:
Two students presented their work at the Canadian Society of Chemical Engineering Conference held in Edmonton in mid-October. They revealed interesting results especially for the production of aerogels when using McMaster's proprietary biomaterial processed through PGX.
Collaboration with The University of Alberta:
The Company has initiated a two-year project with the U of A to develop at least ten new chemical entities (“NCEs”) to be composed of beta glucan impregnated with various bioactives. Physicochemical properties of these NCEs will be tested at U of A, as well as their potential applications in various healthcare sectors. The PGX technology is then a key asset that should enable the transition of Ceapro into a biopharmaceutical company through the development of delivery system(s).
Financial Results for the Three and Nine-Month Periods Ended September 30, 2017
- Total sales of $3,600,00 in Q3 2017 and $9,957,000 for the first nine months of 2017 respectively, compared to $3,018,000 and $11,249,000 in 2016. The increased sales in Q3 2017 over Q3 2016 as well as over Q2 and Q1 2017 are essentially due to an increase in sales of avenanthramides.
- Net profit after tax of $296,000 in Q3 2017 and $684,000 for the first nine months of 2017 compared to $645,000 and $3,494,000 in 2016. Net profit for the first nine-month period is affected by an increase of a non-cash item of $482,000 (2016 – $115,000) primarily related to the grant of stock options in January 2017.
- Research and Development investments net of grants of $435,000 and $1,332,000 for the three and nine-month period of 2017 respectively compared to $265,000 and $531,000 in 2016. The increase relates to additional investments to develop our technologies and expand the product pipelines for our value driver active ingredients and also relates to the timing of recognition of scientific research and development tax credits.
- General and Administration expenses of $587,000 in Q3 2017 and $2,113,000 for the first nine months of 2017 respectively compared to $528,000 and $1,548,000 in 2016. The increase in G&A is primarily due to an increase in salaries and benefits expense relating to the granting of stock options in January 2017 which resulted in an increase in share-based payments in 2017 of approximately $366,000, an increase in management consulting fees, and an increase in public company regulatory, filing and publication fees. While the share based payment accounting charge impacts net income, it has no impact on cash flows.
|Consolidated Balance Sheets|
|September 30,||December 31,|
|Cash and cash equivalents||7,435,743||9,150,035|
|Inventories (note 4)||1,117,071||1,183,428|
|Prepaid expenses and deposits||935,507||371,950|
|Investment tax credits receivable||487,339||487,339|
|Licences (note 5)||28,144||30,366|
|Property and equipment (note 6)||15,915,045||14,324,887|
|Deferred tax assets||–||64,208|
|LIABILITIES AND EQUITY|
|Accounts payable and accrued liabilities||785,318||969,234|
|Deferred revenue (note 8)||21,223||489,613|
|Current portion of long-term debt (note 7)||901,887||1,002,246|
|Current portion of CAAP loan (note 10)||80,814||72,942|
|Long-term debt (note 7)||637,310||1,255,658|
|CAAP loan (note 10)||225,794||201,233|
|Deferred tax liabilities||634,315||–|
|Share capital (note 9 (b))||15,535,450||14,859,136|
|Contributed surplus (note 9 (f))||4,177,838||3,874,725|
|TOTAL LIABILITIES AND EQUITY||27,350,557||26,391,634|
|Consolidated Statements of Net Income and Comprehensive Income|
|Ended September 30,||Ended September 30,|
|Revenue (note 14)||3,600,242||3,017,679||9,956,977||11,249,110|
|Cost of goods sold||1,727,223||1,124,464||4,354,778||3,507,744|
|Research and product development||435,039||264,505||1,332,201||531,086|
|General and administration||586,566||527,856||2,112,592||1,548,360|
|Sales and marketing||730||1,123||9,747||3,952|
|Finance costs (note 13)||21,018||48,887||121,194||196,264|
|Income from operations||829,666||1,050,844||2,026,465||5,461,704|
|Other operating loss (note 12)||(225,686||)||(157,182||)||(653,526||)||(476,461||)|
|Income before tax||603,980||893,662||1,372,939||4,985,243|
|Current tax recovery (expense)||–||–||9,345||(421,916||)|
|Deferred tax expense||(308,410||)||(248,619||)||(698,523||)||(1,069,094||)|
|Income tax expense||(308,410||)||(248,619||)||(689,178||)||(1,491,010||)|
|Total comprehensive income for the period||295,570||645,043||683,761||3,494,233|
|Net income per common share (note 19):|
|Weighted average number of common shares outstanding (note 19):|
About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical, and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company's website at www.ceapro.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Latest posts by Brad Bennett (see all)
- Former XenoPort Chief Medical Officer, Richard Kim, MD, Joins NDA Partners as Expert Consultant - February 21, 2018
- Oral Tradition Transmits Eldersâ€™ Knowledge across Generations in Tsimane Society - February 21, 2018
- Advantest Receives Supplier Excellence Award for Contributing to Start-Up iTestâ€™s Success During its First Year - February 21, 2018